Inclusion Criteria:  Overweight/obese adult males/females 18-75 years of age with a BMI ≥ 27 kg/m2; At least 1 weight-related comorbidity (i.e., hypertension, dyslipidemia, Type 2 diabetes mellitus [T2DM] or prediabetes, or obstructive sleep apnea). Must be ambulatory, willing, and able to wear ABPM monitor apparatus for 24 hours at beginning and end of study.  Exclusion Criteria:  Screening blood pressure of > 140/90 mmHg; Type 1 diabetes; T2DM treated with SFUs, GLP-1 receptor agonists, SGLT inhibitors; or not on stable diabetic medications for at least 3 months prior to randomization; Clinically significant cardiac, hepatic, renal, pulmonary, or thyroid disease; History of bipolar disorder, psychosis, greater than one lifetime episode of major depressive disorder, or presence or history of suicidal behavior or suicidal ideation with intent to act; History of glaucoma; Night shift workers; Obesity of known genetic or endocrine origin; recent history of weight instability, or recent participation in a formal weight loss program within 3 months prior to screening; and Smoking cessation within 3 months prior to screening; Use of antihypertensive medications, antidiabetic medications, statins or other lipid lowering agents, or CPAP therapy that has not been stable for at least 3 months prior to randomization; COVID-19 vaccination or treatment for severe COVID-19 infection within a month prior to randomization.